NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Concord Biotech Q3 Revenue Up 14% YoY to ₹278 Cr; PAT Dips 8.5% on Exceptional Costs
Concord Biotech reported a 13.9% YoY increase in revenue from operations to ₹27,813 lakhs for Q3 FY26. However, Net Profit (PAT) declined by 8.5% YoY to ₹6,778 lakhs, primarily impacted by a one-time exceptional charge of ₹327.54 lakhs related to new labour code regulations. On a sequential basis, the company showed recovery with revenue and PAT growing 12.6% and 7.8% respectively compared to Q2 FY26. The board also strengthened its leadership by appointing Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer.
முக்கிய அம்சங்கள்
Revenue from operations grew 13.9% YoY to ₹27,813.39 lakhs in Q3 FY26 compared to ₹24,422.02 lakhs in Q3 FY25.Net Profit (PAT) for the quarter stood at ₹6,778.27 lakhs, a decline from ₹7,408.88 lakhs in the corresponding quarter last year.Recognized an exceptional item of ₹327.54 lakhs due to the statutory impact of new labour codes on employee benefit obligations.9-month PAT for FY26 shows a significant decline to ₹17,324.46 lakhs from ₹23,102.69 lakhs in the same period last year.Appointed Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the margin pressure as PAT has declined despite healthy revenue growth. The significant year-to-date profit lag compared to the previous fiscal suggests a cautious outlook until bottom-line growth stabilizes.
Concord Biotech Q3 FY26 Revenue Grows 14% to ₹278 Cr; API Segment Surges 24%
Concord Biotech reported a recovery in Q3 FY26 with revenue growing 14% YoY to ₹278 crores, though 9-month revenue remains 5% lower at ₹729 crores due to H1 disruptions. The API business was a major driver this quarter, growing 24% to ₹219 crores, while the formulation segment saw a decline. Reported EBITDA margins stood at 35.6%, impacted by start-up costs for the new injectable facility; however, core margins remain healthy at 40%. Management expects a return to historical growth levels in FY27 as regulatory hurdles clear and the injectable business scales toward its ₹600 crore peak potential.
முக்கிய அம்சங்கள்
Q3 FY26 revenue increased 14% YoY to ₹278 crores, led by strong API performance of ₹219 crores.Adjusted EBITDA margins (excluding start-up and US subsidiary costs) remained stable at 40%.The new injectable facility received WHO GMP certification, targeting a peak revenue of ₹600 crores.9-month PAT stood at ₹64 crores, impacted by ₹3 crores in new labor code provisions and lower other income.Company remains debt-free with cash and bank balances of ₹350 crores as of December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should focus on the scale-up of the injectable facility and the resumption of Middle East tenders as primary growth drivers for FY27. The stock is a recovery candidate as temporary headwinds from H1 FY26, such as CDSCO delays and tariff uncertainties, have largely been resolved.
Concord Biotech Q3 Revenue Up 14% to Rs 278 Cr; EBITDA Margins Impacted by Expansion Costs
Concord Biotech reported a 14% YoY revenue growth in Q3FY26, reaching Rs 278 crore, primarily driven by a 24% surge in the API segment. However, PAT declined by 16% YoY to Rs 64 crore due to commercialization expenses for the new injectable facility and setup costs for its US subsidiary, Stellon Biotech. EBITDA margins compressed to 35.6% from 40.1% a year ago, though normalized margins remain healthy at approximately 40%. The company achieved a significant milestone by receiving WHO-GMP certification for its injectable plant, paving the way for domestic market entry.
முக்கிய அம்சங்கள்
Q3FY26 Revenue grew 14% YoY to Rs 278 crore, led by robust 24% growth in the API segment.EBITDA margins stood at 35.6%, impacted by one-time setup costs; normalized margins are at ~40%.Received WHO-GMP certification for Unit 4 (Injectable facility), enabling domestic brand launches.Established US subsidiary Stellon Biotech Inc. to create a direct commercial footprint in the US market.Appointed Raviraj Karia as the new Chief Financial Officer (CFO) with 23+ years of experience.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the new injectable facility and the performance of the US subsidiary, as these are the primary drivers for future growth despite current margin pressure. The long-term outlook remains positive due to specialized fermentation capabilities and global expansion.
Concord Biotech Approves Q3 FY26 Results; Appoints New Company Secretary
Concord Biotech's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, BSR & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting concerns. Additionally, the company appointed Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer effective February 11, 2026. This appointment fills a key managerial personnel (KMP) role to oversee corporate governance and regulatory filings.
முக்கிய அம்சங்கள்
Board approved unaudited financial results for the third quarter and nine months ended December 31, 2025.Statutory auditors M/s. BSR & Co. LLP issued a Limited Review Report with an Unmodified Opinion.Mr. Paritosh Trivedi appointed as Company Secretary, Compliance Officer, and Nodal Officer.The new appointee brings 5 years of experience in corporate compliance across Textile, IT, and FMCG sectors.The board meeting concluded at 6:22 P.M. on February 11, 2026.
👀 கவனிக்க வேண்டியவை
Investors should examine the detailed financial tables once published to assess revenue and margin performance for Q3. The appointment of a new compliance officer is a routine administrative update and does not impact the company's fundamental value.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Experience
Concord Biotech has appointed Mr. Raviraj Karia as its new Chief Financial Officer, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of experience in the pharmaceutical and healthcare sectors, having held leadership roles at Intas Pharmaceuticals and Claris Lifesciences. His expertise spans multi-billion dollar financing, large-scale M&A, and cost-efficiency programs. This strategic appointment is aimed at strengthening the company's financial discipline and governance as it scales.
முக்கிய அம்சங்கள்
Appointment of Mr. Raviraj Karia as CFO and Key Managerial Personnel effective December 18, 2025Brings over 23 years of experience in pharmaceuticals, healthcare, and private equity sectorsPreviously managed multi-billion dollar financing programs and led major outbound pharma acquisitionsProven track record of reducing borrowing costs by 2-3% annually through financial optimizationExpertise in implementing digital tools like SAP-based MIS and Power BI for financial governance
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move for corporate governance and financial strategy. Monitor the company's future capital allocation and cost-efficiency metrics under the new leadership.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
CONCORDBIO: CFO Lalit Sethi Resigns, Effective January 5, 2026
Concord Biotech Limited announced the resignation of its Chief Financial Officer (CFO), Mr. Lalit Sethi, effective January 5, 2026. Mr. Sethi's resignation is due to personal reasons and early retirement as he approaches age 59. He has submitted his intention to retire early via a letter dated December 8, 2025. The company has ensured a seamless transition, including a complete handover of financial statements and compliance documentation.
முக்கிய அம்சங்கள்
Lalit Sethi, CFO, will retire effective January 5, 2026Resignation is due to personal reasons and early retirement at age 59Trading window closed from December 8, 2025, until 48 hours after the announcement
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition and any potential impact on the company's financial strategy. While the resignation appears amicable, keep an eye on the appointment of the new CFO and their vision for the company.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
